Seeing Is Believing

Currently out of the existing stock ratings of Jason Gerberry, 180 are a BUY (65.93%), 63 are a HOLD (23.08%), 30 are a SELL (10.99%).
Analyst Jason Gerberry, currently employed at BAML, carries an average stock price target met ratio of 60.93% that have a potential upside of 27.02% achieved within 279 days.
Jason Gerberry’s has documented 569 price targets and ratings displayed on 59 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on LLY, Eli Lilly and Company at 15-Dec-2025.
Analyst best performing recommendations are on ARWR (ARROWHEAD PHARMACEUTICALS).
The best stock recommendation documented was for ARWR (ARROWHEAD PHARMACEUTICALS) at 12/1/2025. The price target of $62 was fulfilled within 2 days with a profit of $9.3 (17.65%) receiving and performance score of 88.24.
Average potential price target upside
Analyst name
Rating
Rating initiation date
Current price target
Potential Upside
Previous price target
Date
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Buy
Since 24-Jan-2022
$269
$40.51 (17.73%)
$250
25 days ago
(12-Dec-2025)
17/19 (89.47%)
$45.02 (20.10%)
467
Buy
Since 17-May-2024
$280
$51.51 (22.54%)
$200
1 months 24 days ago
(13-Nov-2025)
5/6 (83.33%)
$46.77 (20.05%)
236
Buy
Since 31-Oct-2023
$237
$8.51 (3.72%)
$188
2 months 2 days ago
(04-Nov-2025)
2/3 (66.67%)
$18.96 (8.70%)
109
Hold
Since 14-May-2025
$235
$6.51 (2.85%)
$251
2 months 3 days ago
(03-Nov-2025)
16/17 (94.12%)
$16.96 (7.78%)
282
Buy
Since 16-Oct-2020
$260
$31.51 (13.79%)
$235
2 months 3 days ago
(03-Nov-2025)
14/15 (93.33%)
$41.96 (19.24%)
483
Which stock is Jason Gerberry is most bullish on?
Which stock is Jason Gerberry is most reserved on?
What Year was the first public recommendation made by Jason Gerberry?